Free tool
FAERS Monitor: Scemblix
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215358 or its brand name (Scemblix, Asciminib Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,492
Serious
2,282
65% of reports
Hospitalization
644
Death reported
390
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue265
- death201
- nausea185
- drug ineffective179
- thrombocytopenia171
- drug intolerance141
- headache141
- diarrhoea138
- rash110
- pleural effusion109
- hypertension106
- arthralgia104
- off label use104
- dyspnoea96
- cytopenia95
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 14 |
| 2020 | 22 |
| 2021 | 33 |
| 2022 | 412 |
| 2023 | 556 |
| 2024 | 716 |
| 2025 | 934 |
| 2026 | 801 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,667 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytopeniaSignal | 95 | 47.1 | 38.6 | 4,209 |
| pleural effusionSignal | 109 | 10.8 | 9.0 | 961 |
| thrombocytopeniaSignal | 171 | 9.2 | 8.0 | 1,250 |
| drug intoleranceSignal | 141 | 8.8 | 7.5 | 970 |
| hypertensionSignal | 106 | 3.0 | 2.5 | 142 |
| fatigueSignal | 265 | 2.1 | 1.8 | 147 |
| rash | 110 | 1.5 | 1.3 | 19 |
| arthralgia | 104 | 1.5 | 1.2 | 18 |
| nausea | 185 | 1.4 | 1.2 | 22 |
| death | 201 | 1.4 | 1.2 | 24 |
| headache | 141 | 1.4 | 1.2 | 13 |
| diarrhoea | 138 | 1.3 | 1.1 | 9 |
| dyspnoea | 96 | 1.0 | 0.8 | 0 |
| drug ineffective | 179 | 0.8 | 0.7 | 8 |
| off label use | 104 | 0.7 | 0.6 | 12 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.